RESUMEN
Ureteral stents are indwelling medical devices that are most commonly used in treating different urinary tract complications like ureteral obstruction, kidney stones, and strictures, and allow normal urine flow from the kidney to the bladder. Tremendous work has been done in ureteral stent technology to meet the clinical demands, however, till-date a gold standard material for ureteral stents has not yet been developed. Many materials such as metal, and synthetic polymers have been published, however, the role of natural biopolymers has not yet been summarized and discussed. There is no detailed review published to explain the role of natural biopolymers in ureteral stent technology. This is the first review that explains and summarizes the role of natural polymer in ureter stent technology. In this review alginate and chitosan polymers are discussed in detail in the fabrications and coating of ureteral stents. It was summarized that alginate polymer alone or in combination with other polymers have been successfully used by many researchers for the manufacturing of ureteral stents with satisfactory results in vitro, in vivo, and clinical trials. However, alginate is rarely used to coat the surface of ureteral stent. On the other hand, only two reports are available on chitosan polymers for the manufacturing of ureteral stents, however, chitosan is largely used to coat the existing ureteral stents owing to their good antibacterial characteristics. Coating procedures can inhibit encrustation and biofilm formation. Nevertheless, the lack of antibacterial efficiency and inadequate coating limit their applications, however, natural biopolymers like chitosan showed significant promises in coating. Overall, the renewable nature, abundant, biocompatible, and biodegradable potential of natural polymer can be established with significant aspects as the ideal ureteral stent. To fully utilize the potential of the natural biopolymers in the ureteral stent design or coatings, an in-depth study is required to understand and identify their performance both in vitro and in vivo in the urinary tract.
RESUMEN
BACKGROUND: The SARS-CoV-2 virus elicited a major public concern worldwide since December 2019 due to the high number of infections and deaths caused by COVID-19. The Omicron variant was detected in October 2021 which evolved from the wild-type SARS-CoV-2 and was found to possess many mutations. Omicron exhibited high transmissibility and immune evasion as well as reduced severity when compared to the earlier variants. Although vaccinated individuals were largely protected against infections in previous waves, the high prevalence of both reinfections and breakthrough infections with Omicron was observed. The aim of this review is to understand the effectiveness of previous infection on subsequent reinfection, given its significance in driving public health policy, including vaccination prioritization and lockdown requirements. METHODS: A comprehensive literature search was conducted using several databases to target studies reporting data related to the effectiveness of the previous infection with SARS-CoV-2 in protecting against the Omicron variant. Screening of the studies, quality assessment and data extraction were conducted by two reviewers for each study. RESULTS: Only 27 studies met our inclusion criteria. It was observed that previous infection was less effective in preventing reinfections with the Omicron variant compared to the Delta variant irrespective of vaccination status. Furthermore, being fully vaccinated with a booster dose provided additional protection from the Omicron variant. Additionally, most infections caused by Omicron were asymptomatic or mild and rarely resulted in hospitalizations or death in comparison to the Delta wave. CONCLUSION: A majority of the studies reached a consensus that although previous infection provides some degree of immunity against Omicron reinfection, it is much lower in comparison to Delta. Full vaccination with two doses was more protective against Delta than Omicron. Receiving a booster dose provided additional protection against Omicron. It is therefore clear that neither vaccination nor previous infection alone provide optimal protection; hybrid immunity has shown the best results in terms of protecting against either Omicron or Delta variants. However, additional research is needed to quantify how long immunity from vaccination versus previous infection lasts and whether individuals will benefit from variant-specific vaccinations to enhance protection from infection.
